India to launch first dengue vaccine, Takeda’s QDENGA, in early 2027

What Happened

India’s drug regulator CDSCO gave its first approval for a dengue vaccine, QDENGA, made by Takeda. The vaccine is set to be sold in the country from early 2027.

Why It Matters

Dengue spreads through mosquito bites and leads to large numbers of hospitalisations every year in many Indian states. Having a locally approved vaccine adds a new tool to the public‑health arsenal, alongside mosquito control and early diagnosis. The approval signals confidence in the vaccine’s safety and effectiveness for the Indian population, which could lower case numbers and reduce pressure on hospitals.

What Happens Next

The vaccine will undergo a phased rollout once it reaches the market, starting with regions that report the highest dengue incidence. Health agencies will monitor its impact on case trends and may adjust vaccination guidelines based on real‑world data. If the vaccine proves effective, it could be integrated into routine immunisation programmes, but the exact timing of widespread use will depend on supply, funding and public acceptance.